KEI sent this letter to USTR today regarding the TRIPS Waiver negotiations. Highlights what we think are the three most important issues. KEI-USTR-TRIPS-waiver-Priorities-18nov2021 November 18, 2021 Ambassador Katherine Tai Office of the United States Trade Representative Washington, DC Dear Ambassador… Continue Reading
On November 16, 2021, Pfizer and the Medicines Patent Pool (MPP) announced at voluntary license to patented inventions and know-how to manufacture a two drug combination to treat COVID-19. The MPP announcement is here and here. Additional comments on the… Continue Reading
November 10, 2021 Andrew Burke, Ph.D. Senior Technology Transfer Manager, NCI Technology Transfer Center, Email: andy.burke@nih.gov. Re: Prospective Grant of an Exclusive Patent License: Development and Commercialization of CRISPR-Engineered T Cell Therapies for the Treatment of Cancer to Neogene Therapeutics… Continue Reading
(For more resources, please see our page on molnupiravir.) According to Brook Baker, these are the countries included in the Merck voluntary license to generic suppliers Afghanistan, Algeria, Angola, Bangladesh, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi, Cambodia, Cameroon,… Continue Reading
October 15, 2021 James Love In the past few days, two documents have been leaked regarding the European Union (EU)’s positions at the World Trade Organization (WTO), in negotiations over which rules if any at the WTO should be waived… Continue Reading
KEI will host a two hour virtual roundtable on march-in rights in U.S. government-funded inventions on Wednesday October 6, 2021 from 2pm to 4pm EDT. This will take place via Zoom, so if you would like to take part in… Continue Reading
The US Federal Register has published a final rule for the “Concrete Masonry Products Research, Education, and Promotion Order.” (Link). The rule is being issued pursuant to Public Law 115-254, the FAA Reauthorization Act of 2018, which is described as… Continue Reading
On September 9, 2021, the Secretary of HHS, Xavier Becerra, pushed a 29 page report on proposals to address high drug prices. “Report To The White House Competition Council, on Comprehensive Plan for Addressing High Drug Prices. A Report in… Continue Reading
PDF version of letter to NIH. Failure2disclose-Doudna-patents-12oct2020 October 12, 2020 Michelle Bulls Director Office of Policy for Extramural Research Administration (OPERA) National Institutes of Health Via Email: michelle.bulls@nih.gov RE: Failures to disclose government funding associated with patents related to “Methods… Continue Reading
Robert Sachs filed this petition with DoD, asking to join an outstanding march-in petition on the patents for the prostate cancer drug enzalutamide, sold under the brand name Xtandi by Astellas. The petition asks that that march-in be granted on… Continue Reading